CD4 and non-small cell lung carcinoma: Besides, human NSCLC cells, including tumor cell lines and primary tumor cells from clinical patients, can efficiently drive metabolic adaptation of human CD4 + T cells, directing differentiation of regulatory T cells while suppressing effector T cells [46].